Cargando…
Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy
In recent years, there has been a plethora of attempts to discover biomarkers that are more reliable than α-fetoprotein for the early prediction and prognosis of hepatocellular carcinoma (HCC). Efforts have involved such fields as genomics, transcriptomics, epigenetics, microRNA, exosomes, proteomic...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074571/ https://www.ncbi.nlm.nih.gov/pubmed/32012846 http://dx.doi.org/10.3390/metabo10020050 |
_version_ | 1783506864274669568 |
---|---|
author | Beyoğlu, Diren Idle, Jeffrey R. |
author_facet | Beyoğlu, Diren Idle, Jeffrey R. |
author_sort | Beyoğlu, Diren |
collection | PubMed |
description | In recent years, there has been a plethora of attempts to discover biomarkers that are more reliable than α-fetoprotein for the early prediction and prognosis of hepatocellular carcinoma (HCC). Efforts have involved such fields as genomics, transcriptomics, epigenetics, microRNA, exosomes, proteomics, glycoproteomics, and metabolomics. HCC arises against a background of inflammation, steatosis, and cirrhosis, due mainly to hepatic insults caused by alcohol abuse, hepatitis B and C virus infection, adiposity, and diabetes. Metabolomics offers an opportunity, without recourse to liver biopsy, to discover biomarkers for premalignant liver disease, thereby alerting the potential of impending HCC. We have reviewed metabolomic studies in alcoholic liver disease (ALD), cholestasis, fibrosis, cirrhosis, nonalcoholic fatty liver (NAFL), and nonalcoholic steatohepatitis (NASH). Specificity was our major criterion in proposing clinical evaluation of indole-3-lactic acid, phenyllactic acid, N-lauroylglycine, decatrienoate, N-acetyltaurine for ALD, urinary sulfated bile acids for cholestasis, cervonoyl ethanolamide for fibrosis, 16α-hydroxyestrone for cirrhosis, and the pattern of acyl carnitines for NAFL and NASH. These examples derive from a large body of published metabolomic observations in various liver diseases in adults, adolescents, and children, together with animal models. Many other options have been tabulated. Metabolomic biomarkers for premalignant liver disease may help reduce the incidence of HCC. |
format | Online Article Text |
id | pubmed-7074571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70745712020-03-20 Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy Beyoğlu, Diren Idle, Jeffrey R. Metabolites Review In recent years, there has been a plethora of attempts to discover biomarkers that are more reliable than α-fetoprotein for the early prediction and prognosis of hepatocellular carcinoma (HCC). Efforts have involved such fields as genomics, transcriptomics, epigenetics, microRNA, exosomes, proteomics, glycoproteomics, and metabolomics. HCC arises against a background of inflammation, steatosis, and cirrhosis, due mainly to hepatic insults caused by alcohol abuse, hepatitis B and C virus infection, adiposity, and diabetes. Metabolomics offers an opportunity, without recourse to liver biopsy, to discover biomarkers for premalignant liver disease, thereby alerting the potential of impending HCC. We have reviewed metabolomic studies in alcoholic liver disease (ALD), cholestasis, fibrosis, cirrhosis, nonalcoholic fatty liver (NAFL), and nonalcoholic steatohepatitis (NASH). Specificity was our major criterion in proposing clinical evaluation of indole-3-lactic acid, phenyllactic acid, N-lauroylglycine, decatrienoate, N-acetyltaurine for ALD, urinary sulfated bile acids for cholestasis, cervonoyl ethanolamide for fibrosis, 16α-hydroxyestrone for cirrhosis, and the pattern of acyl carnitines for NAFL and NASH. These examples derive from a large body of published metabolomic observations in various liver diseases in adults, adolescents, and children, together with animal models. Many other options have been tabulated. Metabolomic biomarkers for premalignant liver disease may help reduce the incidence of HCC. MDPI 2020-01-28 /pmc/articles/PMC7074571/ /pubmed/32012846 http://dx.doi.org/10.3390/metabo10020050 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Beyoğlu, Diren Idle, Jeffrey R. Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy |
title | Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy |
title_full | Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy |
title_fullStr | Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy |
title_full_unstemmed | Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy |
title_short | Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy |
title_sort | metabolomic and lipidomic biomarkers for premalignant liver disease diagnosis and therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074571/ https://www.ncbi.nlm.nih.gov/pubmed/32012846 http://dx.doi.org/10.3390/metabo10020050 |
work_keys_str_mv | AT beyogludiren metabolomicandlipidomicbiomarkersforpremalignantliverdiseasediagnosisandtherapy AT idlejeffreyr metabolomicandlipidomicbiomarkersforpremalignantliverdiseasediagnosisandtherapy |